Safety and tolerability of intravenous ibandronate injections: DIVA 1-year analysis.

被引：0
|
作者：
Drezner, MK
Ste-Marie, LG
Nuti, R
Benhamou, C
Leigh, C
Ward, P
Masanauskaite, D
Lewiecki, EM
机构：
[1] Univ Wisconsin, Madison, WI USA
[2] GRECC, Madison, WI USA
[3] CHUM Hop St Luc, Montreal, PQ, Canada
[4] Univ Siena, I-53100 Siena, Italy
[5] IPROS, CHR, Orleans, France
[6] F Hoffmann La Roche Ltd, Basel, Switzerland
[7] New Mexico Clin Res & Osteoporosis Ctr, Albuquerque, NM USA
来源：
JOURNAL OF BONE AND MINERAL RESEARCH | 2005年 / 20卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S396 / S396
页数：1
相关论文
共 50 条
  • [31] Extended-interval ibandronate injection is an effective and safe alternative to daily oral ibandronate: 1-year results from DIVA.
    Bolognese, MA
    Zaidi, M
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2005, 53 (04) : S193 - S194
  • [32] Intermittent ibandronate injections in postmenopausal osteoporosis: Rationale and design of the dosing intravenous administration (DIVA) study
    Adami, S
    Recker, RR
    Reid, DM
    Kelly, S
    Jonkanski, I
    Gilbride, J
    Bonvoisin, B
    OSTEOPOROSIS INTERNATIONAL, 2003, 14 : S56 - S56
  • [33] Similar safety profile of intravenous ibandronate injection and daily oral ibandronate in postmenopausal osteoporosis: The DIVA study.
    Sambrook, P
    Bianchi, G
    Olszynski, WP
    Leigh, C
    Masanauskaite, D
    Bonvoisin, B
    Emkey, R
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S296 - S296
  • [34] Intermittent intravenous ibandronate injections are associated with newly formed bone of normal quality: The DIVA study.
    Ste-Marie, Louis-Georges
    Langdahl, Bente
    Dieter-Felsenberg
    Czerwinski, Edward
    Hughes, Claire
    Bonvoisin, Bernard
    Masanauskaite, Daiva
    Recker, Robert R.
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S583 - S583
  • [35] Tolerability of monthly oral ibandronate in postmenopausal osteoporosis: 1-year results from the MOBILE study
    Recker, RR
    Silverman, SL
    Kendler, DL
    Dumont, E
    Hughes, BBC
    Reginster, JY
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S293 - S294
  • [36] The DIVA study: Substantial hip bone mineral density improvements with intermittent intravenous ibandronate injections.
    Lewiecki, E.
    Adami, S.
    Bianchi, G.
    Sambrook, P.
    Hughes, C.
    Mairon, N.
    Jonkanski, I.
    Bolognese, M.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 : S70 - S70
  • [37] Consistent bone mineral density gains with intravenous ibandronate injections: Results from the DIVA study.
    Emkey, R
    Halse, J
    Kruse, HP
    Hughes, C
    Ward, P
    Masanauskaite, D
    Recker, RR
    JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (09) : S285 - S285
  • [38] Renal tolerability profile of intravenous ibandronate injection in postmenopausal women with osteoporosis: Findings from the DIVA study.
    Emkey, R
    Olszynski, WP
    Bianchi, G
    Leigh, C
    Masanauskaite, D
    Sedarati, F
    Sambrook, P
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S295 - S296
  • [39] Intermittent intravenous (i.v.) ibandronate injections are more effective than an established daily oral regimen: DIVA 2-year results
    Czerwinski, E.
    Reginster, J. Y.
    Jonkanski, I.
    Neate, C.
    Eisman, J. A.
    OSTEOPOROSIS INTERNATIONAL, 2007, 18 : S127 - S127
  • [40] Effects of intermittent intravenous ibandronate injections on bone quality and micro-architecture in women with postmenopausal osteoporosis: The DIVA study
    Recker, Robert R.
    Ste-Marie, Louis-George
    Langdahl, Bente
    Czerwinski, Edward
    Bonvoisin, Bernard
    Masanauskaite, Daiva
    Rowell, Lucy
    Felsenberg, Dieter
    BONE, 2010, 46 (03) : 660 - 665
12345